Novel antifungal agents: a patent review (2013 - present)

References

• Brown GD, Denning DW, Gow NAR, et al. Hidden killers: human fungal infections. Sci Transl Med. 2012;4:165rv13.
   PubMed Web of Science ®Google Scholar
• Denning DW, Hope WW. Therapy for fungal diseases: opportunities and priorities. Trends Microbiol. 2010;18:195–204.
   PubMed Web of Science ®Google Scholar
• Kontoyiannis D, Mantadakis E, Samonis G. Systemic mycoses in the immunocompromised host: an update in antifungal therapy. J Hosp Infect. 2003;53:243–258.
   PubMed Web of Science ®Google Scholar
• Richardson M, Lass-Flörl C. Changing epidemiology of systemic fungal infections. Clin Microbiol Infect. 2008;14:5–24.
   PubMed Web of Science ®Google Scholar
• Baddley JW, Andes DR, Marr KA, et al. Factors associated with mortality in transplant patients with invasive aspergillosis. Clin Infect Dis. 2010;50(12):1559–1567.
   PubMed Web of Science ®Google Scholar
• Cuenca-Estrella M, Bernal-Martinez L, Buitrago MJ, et al. Update on the epidemiology and diagnosis of invasive fungal infection. Intl J AntimicrobAgents. 2008;32(2):S143–S14.
   Google Scholar
• Pfaller MA, Pappas PG, Wingard JR. Invasive fungal pathogens: currentepidemiological trends. Clin Infect Dis. 2006;43:S3–14.
   Web of Science ®Google Scholar
• Sheng C, Zhang W. New lead structures in antifungal drug discovery. Curr Med Chem. 2011;18:733–766.
   PubMed Web of Science ®Google Scholar
• Marty FM, Ostrosky-Zeichner L, Cornely OA, et al. Isavuconazole treatment for mucormycosis: a single-arm open-label trial and case-control analysis. Lancet Infect Dis. 2016;16(7):828–837.
   PubMed Web of Science ®Google Scholar
• Odds F. Antifungal agents: their divertisty and increasing sophistication. Mycologist. 2003;17:51–55.
   Google Scholar
• Espinel-Ingroff A. Mechanisms of resistance to antifungal agents: yeasts and filamentous fungi. Rev Iberoamer Micol. 2008;25:101–106.
   PubMed Web of Science ®Google Scholar
• Ostrosky-Zeichner L, Casadevall A, Galgiani JN, et al. An insight into the antifungal pipeline: selected new molecules and beyond. Nat Rev Drug Discov. 2010;9:719–727.
   PubMed Web of Science ®Google Scholar
• Calugi C, Trabocchi A, Guarna A. Novel small molecules for the treatment of infections caused by Candida albicans: a patent review (2002-2010). Expert Opin Ther Patents. 2011;21:381–397.
   PubMed Web of Science ®Google Scholar
• Castelli MV, Butassi E, Monteiro MC, et al. Novel antifungal agents: a patent review (2011-present). Exper Opin Ther Patents. 2014;24(3):323–338.
   PubMed Web of Science ®Google Scholar
• Dw D, Bromley MJ. How to bolster the antifungal pipeline. Science. 2015;347(6229):1414–1416.
   PubMed Web of Science ®Google Scholar
• Calderone R, Sun N, Gay-Andrieu F, et al. Antifungal drug discovery: the process and outcomes. Future Microbiol. 2014;9(6):791–805.
   PubMed Web of Science ®Google Scholar
• Gruszecki WI, Gagos M, Herec M, et al. Organization of antibiotic amphotericin B in model lipid membranes. Mini Review Cell Mol Biol Lett. 2003;8:161–170.
   PubMed Web of Science ®Google Scholar
• Gray KC, Palacios DS, Dailey I, et al. Amphotericin primarily kills yeast by simply binding ergosterol. Proc Natl Acad Sci USA. 2012;109(7):2234–2239.
   PubMed Web of Science ®Google Scholar
• Anderson TM, Clay MC, Cioffi AG, et al. Amphotericin forms an extramembranous and fungicidal sterol sponge. Nat Chem Biol. 2014;10:400–406.
   PubMed Web of Science ®Google Scholar
• Cuenca-Estrella M, Gomez-Lopez A, Mellado E, et al. Head-to head comparison of activities of currently available antifungal agents against 3378 Spanish clinical isolates or yeasts and filamentous fungi. Antimicrob Agents Chemother. 2006;50(3):917–921.
   PubMed Web of Science ®Google Scholar
• Kontoyiannis DP. Invasive mycoses: strategies for effective management. Am J Med. 2012;125:S25–38.
   PubMed Web of Science ®Google Scholar
• Baginski M, Czub J. Amphotericin B and its new derivatives–mode of action. Curr Drug Metab. 2009;10:459–469.
   PubMed Web of Science ®Google Scholar
• Chandrasekar P. Management of invasive fungal infections: a role for polyenes. J Antimicrob Chemother. 2011;66:457–465.
   PubMed Web of Science ®Google Scholar
• Espuelas MS, Legrand P, Campanero MA, et al. Polymeric carriers for amphotericin B: in vitro activity, toxicity and therapeutic efficacy against systemic candidiasis in neutropenic mice. J Antimicro Chemother. 2003;52:419–427.
   PubMed Web of Science ®Google Scholar
• ACEA Biotech, Inc., San Francisco, US. Antifungal and antiparasitic polyene macrolides. US 9212201. 2015.
   Google Scholar
• Onyewu C, Blankenship J, Del Poeta M, et al. Ergosterol biosynthesis inhibitors become fungicidal when combined with calcineurin inhibitors against Candida albicans, Candida glabrata and Candida krusei. Antimicrob Agents Chemother. 2003;47:956–964.
   PubMed Web of Science ®Google Scholar
• Kanafani ZA, Perfect JR. Resistance to antifungal agents: mechanisms and clinical impact. Clin Infect Dis. 2008;46:120–128.
   PubMed Web of Science ®Google Scholar
• Pfaller MA, Diekema DJ, Sheehan DJ. Interpretive breakpoints for fluconazole and candida revisited: a blueprint for the future of antifungal susceptibility testing. Clin Microbiol Rev. 2006;19(2):435–447.
   PubMed Web of Science ®Google Scholar
• Alastruey-Izquierdo A, Castelli MV, Cuesta I, et al. Activity of posaconazole and other antifungal agents against mucorales strains identified by sequencing of internal transcribed spacer. Antimicrob Agents Chemother. 2009;53(4):1686–1689.
   PubMed Web of Science ®Google Scholar
• Sanglard D, Coste AT. Activity of isavuconazole and other azoles against candida clinical isolates and yeast model systems with known azole resistance mechanisms. Antimicrob Agents Chemother. 2016;60(1):229–238.
   Web of Science ®Google Scholar
• FDC Limited and Council for Scientific & Industrial Research. Enantiomers of fluconazole analogues containing thieno-[2,-3-D]pyrimidin-4(3H)-one moiety as antifungal agents. US 9181269. 2015.
   Google Scholar
• Clinical and laboratory Stantards Institute (CLSI). Reference Method for Broth Dilution Antifungal Susceptibility Testing of Yeasts; Approved Standard—Second Edition. NCCLS document M27-A2 (ISBN 1-56238-469-4). NCCLS, 940 West Valley Road, Suite 1400, Wayne, Pennsylvania 19087-1898 USA, 2002.
   Google Scholar
• Bowman SM, Free SJ. The structure and synthesis of the fungal cell wall. Bioessays. 2006;28:799–808.
   PubMed Web of Science ®Google Scholar
• Latge JP. The cell wall: a carbohydrate armour for the fungal cell. Mol Microbiol. 2007;66:279–290.
   PubMed Web of Science ®Google Scholar
• Onishi J, Meinz M, Thompson J, et al. Discovery of novel antifungal (1,3)-d-glucan synthase inhibitors. Antimicrob Agents Chemother. 2000;44:368–377.
   PubMed Web of Science ®Google Scholar
• Sucher AJ, Chahine EB, Balcer HE. Echinocandins: the newest class of antifungals. Ann Pharmacother. 2009;43:1647–1657.
   PubMed Web of Science ®Google Scholar
• Pfaller MA, Messer SA, Rhomberg PR, et al. Activity of a long-acting echinocandin, CD101, determined using CLSI and EUCAST reference methods, against Candida and Aspergillus spp including echinocandin- and azole-resistant isolates. J Antimicrob Chemother. 2016;71:2868–2873.
   PubMed Web of Science ®Google Scholar
• Alexander BD, Johnson MD, Pfeiffer CD, et al. Increasing echinocandin resistance in Candida glabrata: clinical failure correlates with presence of FKS mutations and elevated minimum inhibitory concentrations. Clin Infect Dis. 2013;56(12):1724–1732.
   PubMed Web of Science ®Google Scholar
• Mukherjee PK, Sheehan D, Puzniak L, et al. Echinocandins: are they all the same? J Chemother. 2011;23:319–325.
   PubMed Web of Science ®Google Scholar
• Cidara Therapeutics, Inc,San Diego, CA (US). Antifungal agents and uses thereof. US 9217014. 2015.
   Google Scholar
• Krishnan BR, James KD, Polowy K, et al. CD101, a novel echinocandin with exceptional stability properties and enhanced aqueous solubility. J Antibiot. 2016. DOI:10.1038/ja.2016.89
   PubMed Web of Science ®Google Scholar
• Zhao Y, Perez WB, Jiménez-Ortigosa C, et al. CD101: a novel long-acting echinocandin. Cell Microbiol. 2016;18(9):1308–1316.
   PubMed Web of Science ®Google Scholar
• Pelaez F, Cabello A, Platas G, et al. The discovery of enfumafungin, a novel antifungal compound produced by an endophytic hormonema species biological activity and taxonomy of the producing organism. Syst Appl Microbiol. 2000;23:333–343.
   PubMed Web of Science ®Google Scholar
• Scynexis, Inc. Durham (US). Antifungal agents. EP 2326172. 2014.
   Google Scholar
• MerckSharp & Dohme Corp, Rahway (US) and Scynexis, Inc. Research Triangle Park (US). Antifungal agents. EP 2326180. 2013.
   Google Scholar
• Merck Sharp & Dohme Corp. and Scynexis Inc. Antifungal agents. EP2007396. 2013.
   Google Scholar
• Merck Sharp & Dohme Corp. and Scynexis Inc. Antifungal agents. US8188085. 2012.
   Google Scholar
• Merck Sharp & Dohme Corp. and Scynexis Inc. Antifungal agents. US8222255. 2012.
   Google Scholar
• Merck Sharp & Dohme Corp. and Scynexis Inc. Antifungal agents. US7863465. 2011.
   Google Scholar
• Merck Sharp & Dohme Corp. and Scynexis Inc. Antifungal agents. CN101454010. 2012.
   Google Scholar
• Jiménez-Ortigosa C, Paderu P, Motyl MR, et al. Enfumafungin derivative MK-3118 shows increased in vitro potency against clinical echinocandin-resistant candida species and aspergillus species isolates. Antimicrob Agents Chemother. 2014;58(2):1248–1251.
   PubMed Web of Science ®Google Scholar
• Pfaller MA, Messer SA, Motyl MR, et al. Activity of MK-3118, a new oral glucan synthase inhibitor, tested against Candida spp by two international methods (CLSI and EUCAST). J Antimicrob Chemother. 2013;68:858–863.
   PubMed Web of Science ®Google Scholar
• Lepak AJ, Marchillo K, Andes DR. Pharmacodynamic Target evaluation of a novel oral glucan synthasenInhibitor, SCY-078 (MK-3118), using an In Vivo murine invasive candidiasis model. Antimicrob Agents Chemother. 2015;59(2):1265–1272.
   PubMed Web of Science ®Google Scholar
• http://www.scynexis.com/pipeline/pipeline.php ( cited Oct 14 th2016)
   Google Scholar
• Zhang L, Falla TJ. Antimicrobial peptides: therapeutic potential. Expert Opin Pharmacother. 2006;7:653–663.
   PubMed Web of Science ®Google Scholar
• Guaní-Guerra E, Santos-Mendoza T, Lugo-Reyes SO, et al. Antimicrobial peptides: general overview and clinical implications in human health and disease. Clin Immunol. 2010;135:1–1.
   PubMed Web of Science ®Google Scholar
• C3 Jian, Inc., Marina Del Rey, California, United States. Antibacterial and antifungal peptides. US 9072793. 2015.
   Google Scholar
• Wisconsin Alumni Research Foundation. Beta-peptides with antifungal activity. US 9168329. 2015.
   Google Scholar
• University of Utah Research Foundation, Salt Lake City, US. Isolation, identification, and uses of antifungal compounds. US 9139616. 2015.
   Google Scholar
• Tawfik K, Jeffs P, Bray B, et al. Burkholdines 1097 and 1229, potent antifungal peptides from burkholderiaambifaria 2.2N. Org Lett. 2010;12(4):664–666.
   PubMed Web of Science ®Google Scholar
• Polichem SA, Luxembourg. Secondary 8-hydroxyquinoline-7-carboxamide derivatives for use as antifungal agents. US 8969380. 2015.
   Google Scholar
• F2G Limited British Body Corporate, Greater Manchester, Great Britain. 2-oxo-2-(2-phenyl-5,6,7,8-tettrahydro-indolizin-3-yl)-acetamide derivatives and related compounds as antifungal agents. US 8524705. 2013.
   Google Scholar
• F2G Limited, Eccles, Manchester (GB). Pyrrole antifungal agents. EP 2283006. 2015.
   Google Scholar
• Janssen Pharmaceutica,Beerse (BE). Novel antifungal 5,6-dihydro-4H-pyrrolo[1,2-a][1,4]-benzodiazepines and 6H-pyrrolo [1,2-a]][1,4] benzodiazepines substituted with bycyclic benzene derivatives. EP 2668187. 2014.
   Google Scholar
• Meiji Seika Pharma Co., Ltd., Tokyo (JP). Topical antifungal agent. EP 2669274. 2015.
   Google Scholar
• Taisho Pharmaceutical Co., Ltd. Tokyo (JP) and Toyama Chemical Co., Ltd. Shinjuku-ku Tokyo (JP). Amidine compound or salt thereof. EP 2738163. 2016.
   Google Scholar
• Toyama Chemical Co., Ltd., Tokyo, Japan. Arylamidine derivative, salt thereof and antifungal agent containing those. US 8536343 B2. 2013.
   Google Scholar
• Toyama Chemical Co., Ltd., Tokyo, Japan. Arylamidine derivative, salt thereof and antifungal containing these. EP 1767526. 2012.
   Google Scholar
• Toyama Chemical Co., Ltd., Tokyo, Japan. Novel arylamidine derivative or salt thereof. WO A03-074476. 2003.
   Google Scholar
• F2G Limited, Manchester, Great Britain. Dihydroorotate deshydrogenase as antifungal drug target and quinazolinone-based inhibitors thereof. US 9034887. 2015.
   Google Scholar
• Zameitat E, Gojkovic Z, Knecht W, et al. Biochemical characterization of recombinant dihydroorotate dehydrogenase from the opportunistic pathogenic yeast Candida albicans. Febs J. 2006;273:3183–3191.
   PubMed Web of Science ®Google Scholar
• Svetaz L, Postigo A, Butassi E, et al. Antifungal drugs combinations: a patent review 2000-2015. Expert Opin Ther Pat. 2016;26(4):439–453.
   PubMed Web of Science ®Google Scholar